Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) announces the publication of its Annual Report for the year ended 31 December 2008. The filing was submitted on 4 March 2009. The document serves to disseminate the Annual Report to US investors and includes unaudited preliminary results prepared in accordance with IAS 34, along with reclassified consolidated cash flow statements.
Key Financial Metrics
The filing provides specific cash flow data for the year ended 31 December 2008, with comparative figures for 2007. Specific revenue, profit margins, and debt totals are not explicitly detailed in this summary text, though profit after tax is listed.
| Metric | 2008 (£m) | 2007 (£m) |
|---|---|---|
| Profit after tax | 4,712 | 5,310 |
| Cash generated from operations | 9,055 | 8,080 |
| Net cash inflow from operating activities | 7,205 | 6,161 |
| Net cash outflow from investing activities | (1,149) | (3,048) |
| Net cash outflow from financing activities | (4,908) | (1,702) |
| Cash and bank overdrafts at end of year | 5,472 | 3,221 |
| Trade receivables from top 3 US wholesalers | 1,067 | 915 |
Note: The filing notes that cash generated from operations was reclassified downward from £9,161 million (reported in preliminary results) to £9,055 million.
Material Changes and Operational Highlights
- Generic Competition Impact: The US launch of generic products competing with Lamictal, Imitrex, Paxil CR, Requip, and Wellbutrin XL had a significant impact on turnover and earnings for 2008.
- Shareholder Returns: The company engaged in significant share buybacks, purchasing £3,706 million of own shares for cancellation in 2008, compared to £213 million in 2007. Dividends paid to shareholders increased to £2,929 million from £2,793 million.
- Debt and Liquidity: Long-term loans increased by £5,523 million in 2008. Net cash and cash equivalents rose to £5,623 million.
- Wholesaler Concentration: Sales to the three largest US wholesalers accounted for approximately 84% of US pharmaceutical sales, with receivables from these entities rising to £1,067 million.
Risks, Outlook, and Management Commentary
Management highlights several principal risks and uncertainties that could materially affect future performance:
- Patent Expiry and Litigation: Risks regarding the loss of patent protection and ongoing litigation in the US regarding Avandia and Valtrex. Generic competition is expected to continue to erode sales of proprietary products.
- Legal and Regulatory: The Group faces ongoing federal and state investigations in the US regarding pricing, marketing, and reimbursement. Material provisions for legal proceedings were made in 2006, 2007, and 2008, with potential for additional charges.
- Global Economic Conditions: The filing cites extreme financial difficulty in major economies, including liquidity problems and potential recession, which may adversely affect sales and pension plan funding.
- Product Safety and Supply: Risks include regulatory scrutiny on safety (e.g., Avandia sales declines in 2007), potential product recalls, and supply chain interruptions due to manufacturing compliance issues.
- Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to the risks outlined above.
Key Facts for Investor Verification
- Verify the full extent of the impact of generic competition on specific blockbuster drugs (Lamictal, Imitrex, Paxil CR, Requip, Wellbutrin XL) in the full Annual Report.
- Review the status of ongoing US government investigations into pricing and marketing practices and any associated financial provisions.
- Confirm the details of the reclassifications made to the Cash Flow Statement and their impact on operating cash flow metrics.
- Assess the exposure to credit risk given that 84% of US pharmaceutical sales are concentrated among three wholesalers.
- Monitor the outcome of patent litigation concerning Avandia and Valtrex in the US market.